ASP2151, a novel helicase-primase inhibitor, possesses antiviral activity against varicella-zoster virus and herpes simplex virus types 1 and 2 | Zendy

Koji Chono | Zendy; Kiyomitsu Katsumata | Zendy; Toru Kontani | Zendy; M. Kobayashi | Zendy; Keiichi Sudo | Zendy; Tomoyuki Yokota | Zendy; Katsuhiro Konno | Zendy; Yusuke Shimizu | Zendy; Hiroshi Suzuki | Zendy

Open Access

ASP2151, a novel helicase-primase inhibitor, possesses antiviral activity against varicella-zoster virus and herpes simplex virus types 1 and 2

Author(s) -

Koji Chono,

Kiyomitsu Katsumata,

Toru Kontani,

M. Kobayashi,

Keiichi Sudo,

Tomoyuki Yokota,

Katsuhiro Konno,

Yusuke Shimizu,

Hiroshi Suzuki

Publication year - 2010

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkq198

Subject(s) - primase , varicella zoster virus , virology , helicase , herpes simplex virus , biology , herpesviridae , virus , microbiology and biotechnology , biochemistry , viral disease , polymerase chain reaction , reverse transcriptase , rna , gene

To evaluate and describe the anti-herpesvirus effect of ASP2151, amenamevir, a novel non-nucleoside oxadiazolylphenyl-containing herpesvirus helicase-primase complex inhibitor.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research